Hsbc Holdings PLC Buys 1,468 Shares of AxoGen, Inc. $AXGN

Hsbc Holdings PLC grew its stake in AxoGen, Inc. (NASDAQ:AXGN) by 6.5% during the 1st quarter, HoldingsChannel reports. The fund owned 24,174 shares of the medical equipment provider’s stock after purchasing an additional 1,468 shares during the quarter. Hsbc Holdings PLC’s holdings in AxoGen were worth $432,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of AxoGen by 4.6% during the first quarter. Vanguard Group Inc. now owns 2,538,607 shares of the medical equipment provider’s stock valued at $46,964,000 after purchasing an additional 112,679 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of AxoGen by 21.1% during the first quarter. Assenagon Asset Management S.A. now owns 1,001,217 shares of the medical equipment provider’s stock valued at $18,523,000 after purchasing an additional 174,681 shares in the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of AxoGen by 166.0% during the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider’s stock valued at $15,729,000 after purchasing an additional 595,579 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of AxoGen by 13.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider’s stock valued at $12,735,000 after purchasing an additional 91,984 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of AxoGen by 2.2% during the fourth quarter. Deutsche Bank AG now owns 594,843 shares of the medical equipment provider’s stock valued at $9,803,000 after purchasing an additional 12,604 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Canaccord Genuity Group lowered their price target on AxoGen from $26.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $26.00.

AxoGen Stock Down 2.7%

AxoGen stock opened at $15.71 on Wednesday. The stock has a market cap of $722.82 million, a PE ratio of -157.08 and a beta of 1.03. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. AxoGen, Inc. has a one year low of $9.22 and a one year high of $21.00. The stock has a fifty day moving average of $13.26 and a 200 day moving average of $14.37.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.